(MedPage Today) — The novel opioid agonist/antagonist nalbuphine offered relief from chronic cough associated with idiopathic pulmonary fibrosis (IPF), the phase IIb CORAL trial showed.
Nalbuphine extended release (ER) reduced objective cough…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
